Form 4: Standard BioTools Director Acquires Shares Through Restricted Stock Units

Director Thomas D. Carey acquired shares in Standard BioTools Inc. through restricted stock units (RSUs) in lieu of cash compensation.

Summary

• On February 28, 2025, Thomas D. Carey, a director of Standard BioTools Inc., acquired 56,338 shares of common stock through Restricted Stock Units (RSUs).
• The RSUs were granted in lieu of $60,000 in cash compensation for services as a board member.
• The RSUs vest as to 25% on the last day of the last month of each fiscal quarter of 2025, contingent upon continued service.
• Following the transaction, Carey beneficially owns 99,466 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider activity related to compensation. The director taking equity instead of cash is mildly positive.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future.

Future Outlook

The RSUs vest quarterly throughout 2025, contingent on continued service.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. This particular filing reflects compensation practices for board members.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• Granting RSUs in lieu of cash is a common practice to align director interests with shareholder value.
• The vesting schedule of 25% per quarter is a fairly standard vesting arrangement.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares as a sign of confidence in the company.
• The use of RSUs instead of cash compensation can conserve company cash resources.

Key Dates